Q3 2023 Results slide image

Q3 2023 Results

Company overview Innovation: Pipeline overview Cardiovascular Financial review Conclusions Financial performance Immunology Immunology Appendix Innovation: Clinical trials Neuroscience Oncology References Abbreviations Other 52 Investor Relations | Q3 2023 Results NOVARTIS | Reimagining Medicine
View entire presentation